ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACADNYSE / NASDAQHealthcareMid cap

$17.11-$0.48 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$3.7B
P/E
9.5x
EV / EBITDA
30.8x
Revenue
$1.1B
Net margin
36.5%
ROCE
8.1%

-25.3% over the last year

ACADIA Pharmaceuticals Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.3%
3M
-41.1%
6M
-18.3%
1Y
-25.3%
5Y
-10.7%

52-week range

Day change -$0.48 (-2.7%) from $18 to $17 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ACAD, bought on each weekday since 2021.

News & filings

What ACADIA Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthNet margin of 36.5% against a peer median of 8.1%.

Concerns (1)

  • The price is 26.1% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Read moreShow less

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Sector
Healthcare
Shares outstanding
168.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.7B
P/E
9.5x
P/B
3.0x
EV / EBITDA
30.8x
EV / Sales
3.4x
P/S
3.5x
52-week high
$30.57
52-week low
$16.50

Profitability

Operating margin
9.8%
Net margin
36.5%
EBITDA margin
10.9%
ROE
31.9%
ROCE
8.1%
ROA
25.0%
Asset turnover
0.69

Growth

Revenue
$1.1B
Revenue growth, 1Y
11.9%
Revenue CAGR, 3Y
27.5%
Net profit growth, 1Y
72.7%
Free cash flow
$105.1M

Solvency

Current ratio
3.83
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
0.28
Cash / Market cap
4.8%

Where the revenue went

Of every $100 of FY2025 revenue, $36 was left as net income.

ACADIA Pharmaceuticals Inc. income statement flow, FY2025
ACADIA Pharmaceuticals Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$89.0M
RevenueGross profit$982.5M
Gross profitResearch and development$328.8M
Gross profitSelling, general and administrative$548.9M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$104.8M
Operating incomePretax income$104.8M
Interest and other incomePretax income$34.1M
Pretax incomeNet income$138.9M
Tax benefit and otherNet income$252.1M

Revenue and net profit

Revenue grew 11.9% in FY2025; net profit is the dashed line.

ACADIA Pharmaceuticals Inc. revenue and net profit by fiscal year
ACADIA Pharmaceuticals Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$517.2M-$216.0M
FY2023$726.4M-$61.3M
FY2024$957.8M$226.5M
FY2025$1.1B$391.0M

Cash flows

FY2025: $109.8M from operations, $105.1M free after investment (dashed).

ACADIA Pharmaceuticals Inc. operating and free cash flow by fiscal year
ACADIA Pharmaceuticals Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$114.0M-$114.0M
FY2023$16.7M$16.7M
FY2024$157.7M$157.2M
FY2025$109.8M$105.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.1B+11.9%1Y
EBITDA
$116.6M+16.4%1Y
Net profit
$391.0M+72.7%1Y
Cash from operations
$109.8M-30.4%1Y
Free cash flow
$105.1M-33.1%1Y
Revenue CAGR, 3Y
27.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.1B$116.6M$391.0M$105.1M31.9%+11.9%+72.7%

Monthly returns

Month-by-month returns of ACAD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.6B
Liabilities$336.8M
Equity$1.2B
Paid-in capital$3.0B
Retained earnings-$1.8B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ACAD highlighted.

P/E against peers

ACAD trades at 9.5x earnings against a peer median of 24.2x (a 61% discount).

Not shown (no positive earnings and no EV / Sales): RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ACADIA Pharmaceuticals Inc.ACADthis companyP/E ↓ discount$3.7B9.5x3.0x31.9%30.8x
RadNet, Inc.RDNT$4.2B-222.6x3.8x-1.7%16.7x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
Organon & Co.OGN$3.5B18.8x4.7x24.9%9.0x
ICU Medical, Inc.ICUI$3.4B4607.1x1.6x0.0%14.7x
Concentra Group Holdings Parent, Inc.CON$3.2B19.2x8.1x42.3%12.7x
Peer median—24.2x3.4x6.6%13.1x

Year-to-date ROI

ACAD since 1 January, against earlier years.

Historical volatility

ACAD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ACADIA Pharmaceuticals Inc. operating margin by fiscal year
ACADIA Pharmaceuticals Inc. operating margin by fiscal year
DateOperating margin
FY2022-43.2%
FY2023-10.1%
FY20248.8%
FY20259.8%
LineFY2025
Cost of revenueCost Of Revenue$89.0M
Gross profitGross Profit$982.5M
Operating expensesOperating Expense$877.7M
Research and developmentResearch And Development$328.8M
Total expensesTotal Expenses$966.7M
Pretax incomePretax Income$138.9M

Learn while you research

Academy chapters picked for ACADIA Pharmaceuticals Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 9.5 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →